Skip to content

Modulating Default Mode Network Function: A Transcranial Direct Current Stimulation (TDCS) Pilot Study

Modulating Default Mode Network Function: A Transcranial Direct Current Stimulation (TDCS) Pilot Study

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04598152
Acronym
MDMN
Enrollment
4
Registered
2020-10-22
Start date
2018-10-01
Completion date
2020-03-09
Last updated
2022-01-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression, Anxiety

Brief summary

The primary purpose of this research is to gather scientific information about how different people's brains work when they look at different types of pictures. This will help to improve the investigators' understanding of the way the brain works for people who are depressed or anxious, and this knowledge could help lead to better diagnosis and treatment.

Detailed description

In this study the investigators are examining the effects of weak electrical stimulation on brain activity as measured by functional magnetic resonance imaging (fMRI). MRI is a widely used method to obtain high resolution brain pictures that are routinely used for diagnostic and clinical purposes. The electrical stimulation is applied on the scalp with a non-FDA approved method called tDCS (transcranial Direct Current Stimulation), typically equivalent to what a 6V battery would produce (and up to no more than 15V). To compare, an AA battery delivers current at 1.5 volt. While almost unnoticeable to the participants, these currents can still temporarily affect brain activity without causing adverse effects. This stimulation would be applied while the participants are in the MRI scanner so that the brain activity can be measured. The participants will have the opportunity to have a test session with the stimulation outside the scanner to get familiar with it.

Interventions

DEVICETDCS - transcranial direct current stimulation

TDCS involves passing a weak current through the brain. One variant, cathodal TDCS, can be used to temporarily hyperpolarize cortical pyramidal cells, thereby decreasing neuronal connections. TDCS has been explored as a possible treatment for depression, but results to date are mixed. No work has examined whether TDCS can be used in an individually guided manner to target locations in the parietal cortex and alter the patterns of circuitry dysfunction described previously.

Sponsors

Jay Fournier
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Intervention model description

The first part of the study consists of screening procedures that are meant to determine if potential participants are eligible to take part in the remainder of the study. If you qualify to take part in the scanning portion of the study, you will have 2 scanning sessions on separate days approximately a week apart. For each scan session you will undergo a functional Magnetic Resonance Imaging (fMRI) scan that lasts approximately 30 minutes and no more than 1 hour. The total time you will spend for each scan session will be between 1-3 hours. During the scanning session you will receive transcranial direct current stimulation (tDCS). Prior to scanning, sponge-electrodes will be placed on your scalp. These electrodes will be connected to a stimulator. This stimulator will apply weak currents to the brain while the MRI takes pictures of your brain's responses. The stimulation current that you will experience is usually less than a 6-volt battery but may be increased up to 15-volts.

Eligibility

Sex/Gender
ALL
Age
18 Years to 30 Years
Healthy volunteers
No

Inclusion criteria

1. Between 18-30years old 2. Score \> 10 on the QIDS or \> 60 on the PROMIS-A 3. We will use a flexible extreme groups recruitment strategy to ensure an adequate distribution of ESC scores. We will ensure that at least 62% of the sample will be composed of those scoring .5 SD above or below the mean, as measured by the NEO-PI-R. This value corresponds to the expected values assuming a normal distribution of the trait. 4. Normal or corrected to normal vision with contact lenses 5. Able to provide informed consent in English 6. Right-handed (Annett criteria)

Exclusion criteria

1. Have a history of head trauma with loss of consciousness. 2. Have a systemic medical illness that may impact fMRI measures of cerebral blood flow. 3. Meet standard

Design outcomes

Primary

MeasureTime frameDescription
Blood Oxygen Level Dependent (BOLD) Response in the Precuneus During an Emotion Regulation Task Completed During fMRI Scanning.1 week (between baseline and repeat scanning)The investigators will determine the effects of TDCS on BOLD response in the precuneus/posterior cingulate gyrus. The BOLD signal is a measure of regional blood flow in the brain and is used as a proxy for neural activity in specific brain regions. Values below represent pre-post change in BOLD response to the emotion regulation task that participants complete during fMRI scanning. We hypothesize that tDCS applied to the target used in this study will decrease BOLD signal (lower values) during critical components of this task, normalizing function in this region.

Secondary

MeasureTime frameDescription
The Percentage of Patients Who Reported a Side Effect in the Active tDCS Condition But Not the Sham tDCS Condition30 minutes to 1 hour (the period during which the tDCS device was worn) on each of two scan daysPotential side effects (e.g., headaches, dizziness, uncomfortable sensations, etc...) will be assessed after each tDCS and sham-tDCS administration. Side effects were assessed using a standardized form. Count below represents the number of participants who reported a mild or moderate side effect during active tDCS but not sham tDCS.

Countries

United States

Participant flow

Participants by arm

ArmCount
Both Arms Reported Together.
Because only 1 participant entered in the real followed by sham condition, we report baseline variables combined across the arms. All 4 participants received active tDCS. TDCS - transcranial direct current stimulation: TDCS involves passing a weak current through the brain. One variant, cathodal TDCS, can be used to temporarily hyperpolarize cortical pyramidal cells, thereby decreasing neuronal connections. TDCS has been explored as a possible treatment for depression, but results to date are mixed. No work has examined whether TDCS can be used in an individually guided manner to target locations in the parietal cortex and alter the patterns of circuitry dysfunction described previously.
4
Total4

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyLost to Follow-up01

Baseline characteristics

CharacteristicBoth Arms Reported Together.
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
0 Participants
Age, Categorical
Between 18 and 65 years
4 Participants
Age, Continuous23.5 years
STANDARD_DEVIATION 5.3
Ethnicity (NIH/OMB)
Hispanic or Latino
1 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
3 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
PROMIS Anxiety Short Form23.5 units on a scale
STANDARD_DEVIATION 0.6
Quick Inventory Depressive Symptoms11.0 units on a scale
STANDARD_DEVIATION 3.6
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
0 Participants
Race (NIH/OMB)
Black or African American
0 Participants
Race (NIH/OMB)
More than one race
2 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
2 Participants
Region of Enrollment
United States
4 participants
Sex: Female, Male
Female
3 Participants
Sex: Female, Male
Male
1 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 40 / 3
other
Total, other adverse events
4 / 43 / 3
serious
Total, serious adverse events
0 / 40 / 3

Outcome results

Primary

Blood Oxygen Level Dependent (BOLD) Response in the Precuneus During an Emotion Regulation Task Completed During fMRI Scanning.

The investigators will determine the effects of TDCS on BOLD response in the precuneus/posterior cingulate gyrus. The BOLD signal is a measure of regional blood flow in the brain and is used as a proxy for neural activity in specific brain regions. Values below represent pre-post change in BOLD response to the emotion regulation task that participants complete during fMRI scanning. We hypothesize that tDCS applied to the target used in this study will decrease BOLD signal (lower values) during critical components of this task, normalizing function in this region.

Time frame: 1 week (between baseline and repeat scanning)

Population: Because no subjects completed the Active followed by Sham tDCS arm, results are reported for the 3 individuals who completed the Sham followed by Active tDCS arm only.

ArmMeasureValue (MEAN)Dispersion
Active vs Sham Transcranial Direct Current Stimulation During fMRIBlood Oxygen Level Dependent (BOLD) Response in the Precuneus During an Emotion Regulation Task Completed During fMRI Scanning.-.09 arbitrary unitsStandard Deviation 0.36
Secondary

The Percentage of Patients Who Reported a Side Effect in the Active tDCS Condition But Not the Sham tDCS Condition

Potential side effects (e.g., headaches, dizziness, uncomfortable sensations, etc...) will be assessed after each tDCS and sham-tDCS administration. Side effects were assessed using a standardized form. Count below represents the number of participants who reported a mild or moderate side effect during active tDCS but not sham tDCS.

Time frame: 30 minutes to 1 hour (the period during which the tDCS device was worn) on each of two scan days

Population: Because no subjects completed the Active followed by Sham tDCS arm, results are reported for the 3 individuals who completed the Sham followed by Active tDCS arm only.

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Active vs Sham Transcranial Direct Current Stimulation During fMRIThe Percentage of Patients Who Reported a Side Effect in the Active tDCS Condition But Not the Sham tDCS Condition3 Participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026